Regulation and legality

Approved drug, unapproved new drug, compounding bulk substance, research material: four statuses, one word.

Peptides are not one legal category, which is why asking whether peptides are FDA-approved has no single answer. Some peptides are approved prescription drugs: insulin and its analogues, semaglutide, liraglutide, tirzepatide, octreotide, leuprolide, teriparatide, desmopressin, tesamorelin and bremelanotide among them. Many more are unapproved new drugs, which is a specific regulatory status rather than an absence of one. A third set sits in the research-material lane, sold for laboratory use and labelled accordingly.

Approval attaches to a product, not to a molecule name. An approved peptide drug is a particular formulation, made under particular controls, with a label an agency reviewed. A vial of the same nominal compound bought as research material is not that product and does not inherit its status. That is the most consequential fact in this entire subject, and it is the one most marketing copy is built to elide.

Legality follows from that, and it is not a simple yes or no. None of this is legal advice. In practice, enforcement in this market has turned far more on how material is marketed than on what the material is: the FDA warning letters we covered in 2026 said almost nothing about vial contents and a great deal about website claims. The July 2026 advisory committee vote and the closing of the shortage-era compounding lane both reshaped that landscape, and the coverage below works through what each one actually did.

Common questions

Are peptides FDA-approved?

Some are and most are not. Peptide is a chemical description, not a regulatory category, so the question has to be asked about a specific product. Dozens of peptide drugs hold FDA approval. Far more peptides are unapproved new drugs, and a large number are sold only as research material, which is a separate lane with its own labelling rules.

Which peptides are FDA-approved?

Approved peptide drugs include insulin and its analogues, the GLP-1 receptor agonists semaglutide and liraglutide, the dual agonist tirzepatide, octreotide, leuprolide, teriparatide, desmopressin, tesamorelin and bremelanotide, among others. In every case the approval covers a specific manufactured product with a reviewed label, not the molecule name in general use.

Are research peptides legal to buy in the United States?

Material sold and labelled for laboratory research use occupies a real regulatory category, and that category is defined by what the material may be marketed and used for rather than by the molecule in the vial. It is not a licence to market a compound for human use, which is where enforcement in this market has concentrated. None of this is legal advice, and our field guide on research use only sets out how the category actually works.

Is it legal to sell peptides?

That depends far less on the compound than on the claims made around it. The FDA warning letters issued to peptide sellers in August 2026 said very little about what was in the vials and a great deal about what was written on the websites: human-use claims, dosing guidance and therapeutic framing are what moved material out of the research lane in the agency’s reading. None of this is legal advice.

Is peptide therapy FDA-approved?

Peptide therapy is a marketing term, not a regulatory one, and there is no FDA approval category by that name. A clinic using the phrase might be prescribing an approved peptide drug, or dispensing a compounded preparation, or offering something with no approval behind it at all. The phrase does not distinguish between those cases, which is most of why it persists.

What happened to compounded GLP-1 drugs?

A drug-shortage provision allowed compounders to legally supply copies of the largest incretin drugs while those drugs were listed as in shortage. When the shortages were resolved, that lane closed. By September 2026 the FDA was describing some continued compounding as pretextual, a word choice our news coverage of that warning letter takes apart.

Read the evidence

6 pieces on this subject, every finding attributed and every gap stated.

What 'Research Use Only' Actually MeansThree words that appear on almost every vial in this market, widely read as a formality. They describe a real legal category — and understanding it explains most of how this industry is structured.Sep 1, 2026 The FDA Just Had Its Biggest Peptide Meeting in Years. Here's What Actually Happened.An advisory committee recommended six peptides for the compounding bulks list this July — and half the internet misread it. What the vote means, what it doesn't, and the timeline nobody quotes.Aug 31, 2026 Five Warning Letters in One Week. The FDA Just Spelled Out What 'Research Use Only' Does Not Cover.On August 24 the FDA wrote to five US peptide sellers at once. The letters say almost nothing about what was in the vials. They are about what was on the websites.Oct 1, 2026 The Compounding Boom Is Over. Here's What Ended It.For two years, a drug-shortage provision let compounders legally supply the biggest weight drugs in the world. When the shortages closed, so did the lane — and the market is still absorbing it.Sep 1, 2026 The FDA Has a New Word for Compounded Weight Drugs: Pretextual.A September warning letter to one of the largest compounding pharmacies in the country reads less like an inspection report and more like a closing argument.Oct 1, 2026 Peptides, SARMs and Steroids Are Three Different ThingsThey get grouped constantly and they have almost nothing in common — different molecules, different mechanisms, different legal status. Sorting them is the first real step to understanding any of it.Sep 1, 2026

The incretin class Verification The growth-hormone axis

For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication